Drug intelligence / Profile preview

levodoxazosin mesylate

Development stage: Unknown
Lead developer: NCPC New Drug Research & Development
Modality: Small Molecules
Administration: Oral

Overview

Levodoxazosin mesylate is a small molecule alpha-1 adrenergic receptor (ADRA1) antagonist being developed by NCPC New Drug Research & Development (a subsidiary of North China Pharmaceutical Group) for the treatment of benign prostatic hyperplasia (BPH). It is the levo-enantiomer of doxazosin, a quinazoline derivative. By blocking alpha-1 receptors in the smooth muscle of the prostate and bladder neck, levodoxazosin mesylate reduces muscle tone and improves urinary flow in patients with BPH. The development of the single isomer aims to optimize the pharmacological profile compared to the racemic doxazosin. It is currently in Phase 1 clinical trials.

Other names: L-doxazosin mesylate(-)-doxazosin mesylateS-doxazosin mesylate

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on levodoxazosin mesylate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on levodoxazosin mesylate.

Explore the full profile